Status:
UNKNOWN
Evaluation of Triage Options After HPV Testing for Cervical Cancer Screening Among HIV-infected Women
Lead Sponsor:
ANRS, Emerging Infectious Diseases
Collaborating Sponsors:
Institut de Recherche pour le Developpement
International Agency for Research on Cancer
Conditions:
HIV Infections
HPV - Anogenital Human Papilloma Virus Infection
Eligibility:
FEMALE
30-49 years
Phase:
NA
Brief Summary
Cervical cancer is the most common cause of cancer and a leading cause of death among HIV-infected women living in resource-limited settings. Although screening for premalignant lesions is an effectiv...
Eligibility Criteria
Inclusion
- Women
- HIV-1 infection
- Age 30 to 49 years
- In care for HIV infection, receiving or initiating antiretroviral therapy
- Written informed consent given
Exclusion
- HIV-2 infection
- Ongoing pregnancy (evidenced by self-report or clinical examination)
- Previous total hysterectomy
- Severe concomitant disease that, according to the investigators, may contraindicate or compromise participation to the study
- History of cervical cancer screening with treatment for precancerous lesions within the last 12 months
- Differed inclusion
- Ongoing heavy menstruation
- Immediate post-partum (\<12 weeks post delivery)
- Sign of ongoing genital infection (e.g. mucopurulante discharge)
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT03789513
Start Date
March 1 2019
End Date
September 1 2022
Last Update
February 16 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
HIV day care center
Bobo-Dioulasso, Burkina Faso
2
Calmette Hospital
Phnom Penh, Cambodia
3
CEPREF
Abidjan, Côte d’Ivoire